Gilead Sciences, Inc. (NASDAQ:GILD) will begin trading ex-dividend on September 14, 2020. The quarterly dividend payment of $ 0.68 per share is scheduled to be paid on September 29, 2020. The dividend yield based on the latest trading day closing price was 4.27 %. Owners of shares, purchased before the ex-dividend date will be eligible for the dividend.
Dividends History
wpDataTable with provided ID not found!Click Here For More Historical Dividends Of Gilead Sciences, Inc.
Gilead Sciences, Inc. recently reported second quarter financial results on July 30, 2020, after market close, research-based biopharmaceutical firm revealed income for the second quarter of $ 1.11 per share, from the revenue of $ 5,143.00 million. The quarterly earnings reduced 39.01 percent while revenues lowered 9.53 percent compared with the same quarter last year.
Wall street analysts are predicting, GILD to report 2Q20 income of $ 1.45 per share from revenue of $ 5305.03 million. The bottom line results missed street analysts by $ 0.34 or 23.45 percent, at the same time, top line results fell short of analysts by $ 162.03 million or 3.05 percent.
Stock Performance
Shares of Gilead Sciences, Inc. traded low $ -0.74 or -1.15 percent on Thursday, reaching $ 63.77 with volume of 8.42 million shares. Gilead Sciences, Inc. has traded high as $ 65.04 and has cracked $ 63.55 on the downward trend
According to the previous trading day, closing price of $ 63.77, representing a 5.95 % increase from the 52 week low of $ 60.89 and a 24.96 % decrease over the 52 week high of $ 85.97.
The company has a market capital of $ 79.95 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The companys products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.
